Emerging within the UK, retatrutide, a new molecule, is generating considerable interest within the scientific community regarding its promise for weight regulation. This dual GIP and GLP-1 receptor agonist seems to offer a significant advantage over existing therapies, showing promising results in early clinical assessments. Researchers suggest it